Here are the DEF 14A proxy statements from Sutro Biopharma, Inc. (STRO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow STRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STRO filings page.
Sutro Biopharma, Inc. is holding a virtual 2026 Annual Meeting of Shareholders on June 5, 2026. Stockholders will vote to elect three Class II directors (Jane Chung, Connie Matsui and James Panek) for three-year terms, ratify Ernst & Young LLP as auditor for 2026, and approve on an advisory basis the compensation of named executive officers.
Stockholders of record at the close of business on April 7, 2026, when 16,567,887 common shares were outstanding, may vote. The board is majority independent, with separate Chair and CEO roles and active Audit, Compensation, Nominating and Governance, and Science and Technology Committees. The proxy describes a pay-for-performance executive compensation program emphasizing equity awards and annual incentives, and notes prior Say-on-Pay support of 77.7% in 2025.